ERBB2 and breast cancer: Due to the fact that this deregulation occurs in Hormone receptor positive (HR+) disease, HER2-amplified and TN tumors, targeting the key components of the PI3K/AKT pathways seem a reasonable option for the treatment of all BC subtypes (27).